Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer.  Ascenta’s current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

June 4, 2010:
Ascenta Therapeutics Liscences Cancer Drug Candidates to Sanofi-Aventis

October 26, 2009:
Ascenta Therapeutics Announces Presentation of Results from a Dose-Ranging Study of AT-101 with Standard Therapy in Patients with Glioblastoma Multiforme

September 10, 2009:
Ascenta Therapeutics Receives Clearance to Initiate Clinical Trials with AT-406

Corporate Fact Sheet

• 2009

Ascenta is developing drugs that target three distinct pathways to cancer cell apoptosis (cell death):

• AT-101 a pan Bcl-2 inhibitor
• AT-406 a multi-IAP antagonist
• HDM2-p53 inhibitor

Ascenta Therapeutics signed a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death).  These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.

Learn More >>